Standard BioTools Inc. Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised
Standard BioTools Inc. (LAB) reported Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised of $120.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans · last filed 2026-08-05
- Standard BioTools Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-12-31 was $215.00K, a 56.39% decline year-over-year.
- Standard BioTools Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-09-30 was $0.00.
- Standard BioTools Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2024-12-31 was $493.00K, a 24.18% increase year-over-year.
- Standard BioTools Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2024-09-30 was $0.00.
- Standard BioTools Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2025 was $523.00K, a 43.03% decline from fiscal 2024.
- Standard BioTools Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2024 was $918.00K, a 26.97% increase from fiscal 2023.
- Standard BioTools Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2023 was $723.00K, a 11.83% decline from fiscal 2022.
- Standard BioTools Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2022 was $820.00K, a 36.19% decline from fiscal 2021.
| Period end | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 3 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 6 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 9 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $120.00K 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $215.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $215.00K derived: sum of 2 quarters · filed 2026-03-16 | $523.00K 10-K · filed 2026-03-16 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $308.00K 10-Q · filed 2025-11-04 | ||
| 2025-06-30 | $308.00K 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $493.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $493.00K derived: sum of 2 quarters · filed 2026-03-16 | $918.00K 10-K · filed 2026-03-16 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $425.00K 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | $425.00K 10-Q · filed 2025-08-15 | |||
| 2023-12-31 | $397.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $397.00K derived: sum of 2 quarters · filed 2026-03-16 | $723.00K 10-K · filed 2026-03-16 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $326.00K 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $326.00K 10-Q · filed 2024-08-06 | |||
| 2022-12-31 | $323.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $323.00K derived: sum of 2 quarters · filed 2025-03-11 | $820.00K 10-K · filed 2025-03-11 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $497.00K 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | $497.00K 10-Q · filed 2023-08-08 | |||
| 2021-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $600.00K derived: sum of 2 quarters · filed 2022-11-09 | $1.28M 10-K · filed 2022-03-08 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $685.00K 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $685.00K 10-Q · filed 2022-08-09 | |||
| 2020-12-31 | $678.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $678.00K derived: sum of 2 quarters · filed 2022-03-08 | $1.32M 10-K · filed 2022-03-08 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $645.00K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $645.00K 10-Q · filed 2021-08-06 | |||
| 2019-12-31 | $434.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $434.00K derived: sum of 2 quarters · filed 2022-03-08 | $1.07M 10-K · filed 2022-03-08 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $641.00K 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | $641.00K 10-Q · filed 2020-08-07 | |||
| 2018-12-31 | $641.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $641.00K derived: sum of 2 quarters · filed 2021-02-25 | $1.20M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $562.00K 10-Q · filed 2019-11-08 | ||
| 2018-06-30 | $562.00K 10-Q · filed 2019-08-07 | |||
| 2017-12-31 | $222.00K 10-K · filed 2020-02-27 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |